Stockreport

Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF Dosing of the first patient in the dose expansion part of the trial triggers a €4m milestone payment to Innate MARSEILLE, France, April 15, 2024 BUSINESS WIRE )--Regu [Read more]